Provider Update

Idursulfase to require prior authorization

Summary of change: Effective May 1, 2018, the injectable medication idursulfase will require prior authorization (PA).

Idursulfase will require PA, and all requests must be reviewed by Amerigroup Iowa, Inc. for PA for dates of service beginning on or after May 1, 2018. Please refer to the provider self-service tool for detailed authorization requirements. Go to https://providers.amerigroup.com, select your state, then under Provider Resources & Documents select Quick Tools/Precertification Lookup Tool.

Please note: These drugs may not be covered in all states. Providers must review their specific state for coverage because not all drugs in this update will apply to the state in which you participate.

Non-compliance with the new requirements may result in denied claims. PA requirements will be added to the following code:

- J1743 — Injection, idursulfase, 1 mg

Please use one of the following methods to request PA:

- **Phone:** 1-800-454-3730
- **Fax:** 1-800-964-3627
- **Web:** https://www.Availity.com

Federal and state law, as well as state contract language (this includes definitions and specific contract provisions/exclusions) take precedence over these PA rules and must be considered first when determining coverage.

What if I need assistance?
If you have questions about this communication or need assistance with any other item, call Provider Services at 1-800-454-3730.